• Surgery risk for IBD declining in biologic era, ‘but that doesn't mean it's zero'

    4 monthes ago - By Healio

    Although the rate of surgery for inflammatory bowel disease has declined significantly in the era of biologic therapy, “it is still occurring,” according to a presenter at the Crohn's and Colitis Congress.
    “If you think in terms of risk, about what the most disabling situation is when it comes to ulcerative colitis, it's probably surgery, and most patients would like to avoid this at any cost,” Angelina Collins, MSN, ANP‐BC, from the Inflammatory Bowel Disease Center at UC San Diego Health, told attendees. “There is hope that the amount of surgery
    Read more ...

     

  • IBD therapies ‘still plateauing' despite progress: Combining drugs may help break ceiling

    IBD therapies ‘still plateauing' despite progress: Combining drugs may help break ceiling

    4 monthes ago - By Healio

    Despite the considerable progress made in the care of inflammatory bowel disease, current therapies are “still plateauing” in terms of response and remission, according to the keynote speaker at the Crohn's and Colitis Congress.
    However, combining therapies with “complementary mechanisms of action” may offer one strategy to help overcome this therapeutic plateau.
    “We have come a long way,” Jean-Frederic Colombel, MD, professor of gastroenterology at the Icahn School of Medicine at Mount Sinai, told attendees. “You have to realize that 30 years
    Read more ...